BCS? [Design Issues]
❝ With nothing published this will be a tough job (I wouldn’t even think about it). Even if one overcomes all these obstacles, the risk assessment will be the show-stopper.
Goodmorning Europe and Hello ROW,
Helmut, would you mind expanding a tad on what you mean by the risk assessment being a party pooper? Is it because mebeverine doesn't have much of a history (sparce published literature data, as you mentioned) or any post-marketing data? Are you talking pharmacovigilance here?
Although we haven't personally gone the BCS biowaiver route yet, it would be useful to have a more comprehensive understanding of the process.
Thanks.
Complete thread:
- mebeverine A-M-R 2012-11-22 11:32
- mebeverine drgunasakaran1 2012-11-22 11:47
- mebeverine bioequivalence A-M-R 2012-11-22 12:12
- mebeverine drgunasakaran1 2012-11-22 11:47
